Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

However, antibody depletion of CTLs reversed this effect, emphasizing the role of CTLs in IL-3-mediated tumor control. To further explore the effect of IL-3 on CTLs, the researchers cultured the cells ...

B-cell lymphoma, a type of cancer that starts in white blood cells called lymphocytes ... levels of functional MHC-II molecules. They found depletion of the BAP1 gene in B-cell lymphoma cells ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...

Houman Ashrafian Head of Research and Development, Sanofi "Deep B-cell depletion is at the frontier of treating autoimmune diseases and using the myeloid cell engager DR-0201 has the potential to ...